Actively Recruiting
Antiviral Therapy for Patients With Liver Cancer After Surgery
Led by Xiangya Hospital of Central South University · Updated on 2022-07-20
360
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF) on patients after radical surgery for hepatitis B associated hepatocellular carcinoma by collecting data from patients at our hospital
CONDITIONS
Official Title
Antiviral Therapy for Patients With Liver Cancer After Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years, any gender
- Patients with hepatocellular carcinoma after radical surgical resection or radiofrequency ablation
- Positive for hepatitis B surface antigen (HBsAg)
- No residual tumor on intraoperative pathology and imaging shows complete remission within 4 weeks after surgery
- Suitable for receiving peginterferon and nucleoside (acid) analog therapy as assessed by investigator
- Signed informed consent form or consent provided by legal guardian or agent
You will not qualify if you...
- Currently receiving hepatotoxic drugs, immunosuppressants, targeted drug therapy, or adjuvant chemotherapy after surgery
- Past or current other malignant tumors except cured skin basal cell or squamous cell carcinoma and cervical carcinoma in situ
- Allergy to interferon alpha or its components, or judged unsuitable for interferon alpha use
- Co-infection with HAV, HCV, HDV, HEV, HIV or other chronic liver diseases including alcoholic liver disease, genetic metabolic liver disease, drug-induced liver disease, non-alcoholic fatty liver disease
- Autoimmune diseases including autoimmune liver disease and psoriasis
- Neutrophil count below 1.5 x 10^9 cells/L or platelet count below 80 x 10^9 cells/L
- Creatinine above 1.5 times the upper normal limit
- Serious diseases of heart, lung, kidney, brain, blood or other major organs
- Severe neurological or psychiatric diseases such as epilepsy, depression, mania, seizures, or schizophrenia
- Unstable diabetes, hypertension, thyroid disease, or history of severe retinopathy
- Child-Pugh grade C liver function
- Drug abuse or alcoholism
- Infection, bleeding, or postoperative complications that make participation unsuitable
- Evidence of liver cancer recurrence or metastasis at baseline
- Pregnant or breastfeeding, or planning pregnancy and unwilling to use contraception during the study
- Investigator assessment that participation is unsuitable
- Participation in other clinical trials at the same time
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangya Hospital of Central South University
Changsha, Hunan, China, 417100
Actively Recruiting
Research Team
L
Ledu Zhou, PhD student
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here